智通财经APP获悉，据港交所9月4日披露，健康160国际有限公司(以下简称：健康160)通过港交所主板 上市聆讯，申万宏源香港、清科资本为其联席保荐人。 | 鳥纂]之[編纂]數目 : [編纂]股股份(視乎[編纂]行使與否而 | 定) | | --- | --- | | [編纂]數目 .. | [編纂]股股份(可予[編纂]) | | [編纂]數目 : | [編纂]股股份(可予[編纂]及視乎[編纂] | | | 行使與否而定) | | 最高 编纂] : | 每股[編纂][編纂]港元,另加1.0% | | | 經紀佣金、0.0027%證監會交易徵 | | | 費、0.00565%香港聯交所交易費及 | | | 0.00015%會財局交易徵費(須於申請 | | | 時以港元繳足,多繳股款可予退還) | | . 面值 | 每股股份[0.000002]美元 | | 股份代號 | : [編纂] | 据招股书，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。该公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。在批发及零售模式下，提供一系列 优质的医药健康用品，以满足客户的不同需求。 ...

Core Insights - Hims & Hers Health's stock price increased by over 7.7%, reaching $44.75, reflecting positive market sentiment since its establishment in 2017 [1] - The company aims to transform how individuals access and manage healthcare services through a consumer-centric health and wellness platform [1] Company Overview - Hims & Hers connects patients directly with licensed medical professionals via a digital healthcare ecosystem [1] - The platform offers medical solutions across various fields, including sexual health, dermatology, hair loss, mental health, and weight management [1] - The business model emphasizes "personalization" and "accessibility," utilizing telehealth consultations, digital prescriptions, and subscription-based medication delivery [1] Technological Innovation - The company employs proprietary algorithms and integrates electronic health record systems, creating an efficient closed-loop digital healthcare service [1] - Hims & Hers aims to enhance user experience and provide high-quality, personalized medical support through technological innovation [1] Market Position - With the ongoing expansion of the telehealth and digital health market, Hims & Hers is positioned to play a significant role in the digital transformation of the healthcare industry [1] - The company is expected to attract more consumers and investors interested in healthy lifestyles [1]

Core Viewpoint - Hims & Hers Health has seen a stock price increase of over 7.7%, reaching $44.75, reflecting strong market interest in its consumer-centric health platform since its establishment in 2017 [1] Company Overview - Hims & Hers Health aims to transform the way individuals access and manage healthcare services by creating a digital health ecosystem that connects patients directly with licensed medical professionals [1] - The company offers a range of medical solutions across various fields, including sexual health, dermatology, hair loss, mental health, and weight management [1] - The platform utilizes proprietary algorithms and integrates electronic health records, along with partnerships with pharmacies, to create an efficient closed-loop digital healthcare service system [1] Business Model - The business model emphasizes "personalization" and "accessibility," lowering barriers to healthcare services through telehealth consultations, digital prescriptions, and subscription-based medication delivery [1] - Hims & Hers aims to enhance user experience through technological innovation, providing high-quality, personalized medical support and setting new standards in health management [1] Market Position - With the ongoing expansion of the telehealth and digital health market, Hims & Hers is positioned to play a significant role in the digital transformation of the healthcare industry, attracting consumers and investors focused on healthy lifestyles [1]

9月2日市场消息称，数字医疗健康科技企业丁香园正积极筹备港交所上市，最快将于年内正式递交招股说明书，启动IPO进程。 值得关注的是，丁香园虽主业定位为连接医生、患者、医院、生物医药企业、科研机构及大众消费品企业等的数字平台型企业，其核心在于内容分享、医疗 数据积累与数字医疗服务，但在大众视野中，其旗下媒体矩阵早已成为健康科普信息的标杆，在化妆品产业科普领域也具有较高影响力。 若消息属实，丁香园的赴港上市事宜将不仅是国内头部互联网医疗企业IPO潮的一朵浪花，更意味着国内科普领域媒体机构同样能叩响资本市场的大门，受 其影响，化妆品行业消费者理性化、专业化的趋势还将进一步加深，但由于信任危机，能否实现IPO尚未可知。 01. 医学专业论坛起家 构建"科普帝国" 丁香园官网显示，该企业创立于2000年，最初以医学专业论坛起家，逐步发展为涵盖医学知识库、在线诊疗、科普内容及产业服务的多元化平台，期间接连 获得资本青睐： 第三方数据显示，丁香医生微信公众号长期稳居健康类自媒体榜首，多篇推送阅读量达百万级，微博账号粉丝超千万。这一影响力不仅实现流量转化，更为 其在线问诊、电商导流等衍生业务奠定了坚实基础。 2010年，该企 ...

9月2日，据IPO早知道消息，数字医疗健康科技企业丁香园正在筹备赴港上市，最快将于今年内向港交所递交招股书。 丁香园由李天天于2000年7月创立，最早从BBS论坛起步。公司最初致力于为医药及生命科学领域人士提供专业性交流平台，现已发展成为连接医生、患 者、医院、生物医药企业等的综合性平台。 丁香园创始人、董事长李天天强调"科普发挥的作用，一个是辟谣，一个是消除焦虑"，并特别关注低收入、社交人群较少群体容易受谣言影响的问题。 有媒体报道称，丁香园已服务上亿大众用户，并拥有超900万专业用户，占全国卫生技术人员的八成，其中包含超405万医生，覆盖比例超过90%。面向专业 医生，丁香园旗下拥有"用药助手"(药品信息查询工具)、丁香园Insight(医药政策与市场信息)、丁香人才(医疗专业招聘)等一系列产品。 同时，面向大众用户的产品包括"丁香医生"(健康科普、在线问诊)、"丁香妈妈"(母婴健康)、丁香生活研究所(健康消费指南)等，通过文章、视频、在线咨询 等形式，提供健康科普、知识服务、在线问诊和健康产品电商等服务。 2016年，丁香园在杭州开设了首家线下诊所，探索医疗服务的零售化模式，注重服务而非单纯开药，药占比 ...

这意味着，这家成立已25年之久的企业终于有望迎来"IPO里程碑"。 最早可追溯至2000年的丁香园从BBS论坛起步，彼时的定位是一个为医生提供学术交 流的平台；2007年前后，丁香园开始商业化运营，曾陆续尝试过招聘、To B电商、营销解决方案等业务模式。 截至目前，丁香园已服务上亿大众用户，并拥有超900万专业用户，占全国卫生技术人员的80%，其中包含超405万医生用户，覆盖全国超过90%的医生。 当然，除了为医生提供学术交流和临床支持外，丁香园在C端更大的知名度还是在于通过微信、抖音、视频号等大众平台，将专业的医学知识传递给公 众。 据消息称，数字医疗健康科技企业「丁香园」正筹备赴港上市，最快今年正式向港交所递交招股说明书。 ...

Core Viewpoint - The launch of the "Bei Daifu" AI assistant at Peking University Shenzhen Hospital aims to enhance the patient experience by providing a comprehensive, one-stop intelligent health service that addresses common pain points in the medical process [1][2]. Group 1: AI Assistant Features - "Bei Daifu" is designed to optimize the entire outpatient process, integrating 27 medical service nodes from pre-consultation to post-consultation, thus alleviating issues like waiting and confusion for patients [2]. - The AI assistant offers 24/7 online intelligent guidance, helping patients with appointment scheduling, directions, and other in-hospital services, effectively answering common queries during their visit [2]. - Patients will receive real-time notifications throughout their medical journey, ensuring they are aware of the next steps and reducing the likelihood of missing appointments [2]. Group 2: Technological Collaboration - The "Bei Daifu" AI assistant is a collaborative effort between Peking University Shenzhen Hospital and Ant Group's digital healthcare division, utilizing the advanced Ant BaiLing model technology to create a smart cloud companion for patients [1][3]. - The hospital has been recognized as a construction unit for artificial intelligence hospitals in Shenzhen, indicating its commitment to integrating AI technologies in various medical and service scenarios, including imaging diagnostics and tumor screening [3].

神州医疗 "唐胖智健"大模型落地，填补肥胖防控智能化建设空白 8月23日，空军军医大学唐都医院与神州医疗科技股份有限公司联合研发的"唐胖智健"AI肥胖大模型正式发 布。 该大模型以权威医疗指南和高质量专家共识为基础， 深度融合唐都医院在肥胖防控领域的优势临床资源与 科研成果及最新医学证据，同步引入神州医疗DHC多模态融合架构和基础模型医疗推理引擎两大技术 ，通 过医研融合、数字驱动，全力构建科研与临床深度融合的肥胖防控体系，充分做到体重管理关口前移，推 动全生命周期的体重管理干预，建立科学完备的"风险识别-病因分型-精准管理"的三级预防网络。其核心价 值在于，对肥胖患者进行"诊前-诊中-诊后"全流程的管理，将肥胖管理前移、深化、贯穿始终。 英矽智能 AI工具助力抗衰老治疗方案开发 近日，英矽智能的研究团队在《衰老 》（ Aging-US） 期刊上发表了一项研究，利用人工智能方法探讨了特 发性肺纤维化 （IPF） 中与衰老相关的生物学机制。IPF是一种慢性、进行性的肺部疾病，主要表现为肺部 正常组织逐渐被瘢痕 （纤维化） 替代，导致肺功能不可逆性下降，最终引发呼吸衰竭。IPF主要影响60岁以 上的人群，被认为与 ...

以下文章来源于东四十条资本 ，作者蒲凡 将投中网设为"星标⭐"，第一时间收获最新推送 东四十条资本 . 聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 对于很多VC/PE来说，今年是一个"流血大年"。 作者丨 蒲凡 来源丨 东四十条资本 如果说2023年的股市关键词是"迷茫"，2024年的股市关键词是"激荡"，那么2025年的股市关键词，很多人大概率会首先想 到"昂扬"。 2025年，大A逐渐站稳了"慢牛"的状态，指数慢条斯理地不断站上高点，寒武纪顺利取代了茅台成为新的"计量单位"，"酱香 科技"也终于在这个过程中成为了一个"过气的梗"。而美股那边，Chime、Figma、Circle、CoreWeave等独角兽顺利完成 IPO，实打实地为市场补充了流动性。其中Figma上市两天内股价上涨了270%的表现，让很多人都相信市场已经进入了复苏 阶段。 然而大先生说得好，人和人的悲欢并不相同。对于很多股民来说，今年当然刺激、昂扬。但对于很多VC/PE来说，今年却是 一个"流血大年"。 据最新的一份统计报告显示， 2025 年迄今为止，有约 16% 的 IPO 相较于最 ...

Core Insights - The core viewpoint of the article highlights the significant transformation and positive financial performance of Zhiyun Health, driven by its AI-powered P2M strategy, which has led to a substantial increase in gross margin and revenue growth [1][2][5]. Financial Performance - Zhiyun Health reported a revenue of 890 million yuan for the first half of 2025, marking a year-on-year increase of 20.3% compared to 740 million yuan in the same period last year [2][3]. - The adjusted gross margin rose by 4.2 percentage points to 49.9%, up from 45.7% in the previous year, reflecting a strong improvement in profitability [2][3]. - The adjusted net loss narrowed by 23.3% to 63.4 million yuan from 82.64 million yuan year-on-year, indicating a positive trend in financial health [2][3]. - Operating cash flow turned positive for the first time, reaching 28.65 million yuan, a significant turnaround from a cash outflow of 195 million yuan in the same period last year [4][3]. Business Strategy and Growth - The P2M (Patient to Industry) solutions revenue surged by 142.1% year-on-year, reaching 260 million yuan, showcasing the effectiveness of the company's strategic shift towards high-value business models [5][6]. - The P2M solutions now contribute 77.5% of the overall gross profit, with in-hospital and out-of-hospital solutions achieving gross margins of 74.9% and 77.8%, respectively [3][5]. - The company has developed a diverse product pipeline with six core products targeting chronic diseases, which is expected to provide stable cash flow and long-term growth [5][6]. AI Technology Integration - The growth of the P2M business is significantly supported by AI technology, with the implementation of ClouD GPT and ClouD DTx models enhancing the company's operational capabilities [6]. - The AI models have established a complete closed loop from medical data accumulation to commercialization, ensuring the effective delivery of P2M products to healthcare providers and patients [6]. - As of June 2025, the company has deployed its SaaS system in over 2,700 hospitals and nearly 270,000 pharmacies, continuously optimizing its AI models with real-world medical data [6]. Future Outlook - The company aims to further solidify its SaaS infrastructure advantages in hospitals and pharmacies while deepening the application of AI technology to accelerate the commercialization of its P2M pipeline [6]. - With ongoing technological and structural improvements, Zhiyun Health is positioned to lead in the digital transformation of chronic disease management, contributing to high-quality industry development [6].